Deep Tech Startup News

Deep tech companies commercialise hard science rather than software alone: a new battery chemistry, a reactor design, a drug candidate, a robot that works outside a lab. What they share is a long, expensive path between the first cheque and the first revenue, because the risk being funded is whether the technology works at all, not whether customers want it. That changes how their rounds read - a large raise can mean a company is years from a product, not close to one.

That profile also makes deep tech the segment where private capital matters most. Public markets rarely fund a decade of pre-revenue research, so the important valuation events happen privately, and the eventual IPO or acquisition prices work that was already done. Coverage here groups biotech, robotics, hardware, energy, defence, and security together because they behave alike as investments, even when the science does not.